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If “a rose by any other name would smell as 
sweet”, then does garbage by any other name 
smell as foul? Before I argue the affirmative, I must 
first fully disclose that like every other neuropa-
thologist, I’ve previously used the term “neuroepi-
thelial tumor” in my own reports and manuscripts. 
Nevertheless, I’ve been increasingly concerned that 
its usage is now pursuing an alarming crescendo 
with an inversely decreasing specificity. 
In the 2015 World Health Organization (WHO) 
consensus meeting in Heidelberg, a decision was 
made to abandon the term, “primitive neuroecto-
dermal tumor” or PNET from the subsequent 2016 
scheme1 and this was generally hailed as a major 
breakthrough, with the promise of enhancing our 
diagnostic accuracy for central nervous system 
(CNS) tumor classification. Nonetheless, it was rec-
ognized that even with improved definitions, one 
still encounters occasional “PNET-like” cases that 
do not conform to currently known entities. As 
such, it was decided to introduce the term, CNS 
embryonal tumor, NOS for such cases. Of course, 
everyone recognized that this was essentially trad-
ing in one trash can for another, but with the no-
tion that the new trash can was smaller and with 
the hope that as additional entities are elucidated 
over time, eventually this category would disappear 
altogether. Also, given that in 2013, the soft tissue 
and bone blue book similarly ditched “peripheral 
PNET” in favor of Ewing sarcoma2, this new ap-
proach essentially eliminated the diagnosis of 
“PNET” altogether. 
Unfortunately, since the WHO 2016 publica-
tion1, I feel that our trash can is yet again expand-
ing, given that the term “neuroepithelial tumor” 
(NET) is gaining momentum, both within the litera-
ture and in clinical practice. For instance, whereas 
we previously had only two known NET entities, 
dysembryoplastic neuroepithelial tumor (DNET) 
(don’t even get me started on “dysembryoplastic”) 
and cribriform neuroepithelial tumor (CRINET), 
we’ve since added: 1) high-grade neuroepithelial 
tumor (HGNET) with MN1 alteration (HGNET-MN1), 
2) HGNET with BCOR exon 15 internal tandem du-
plication (HGNET-BCOR), 3) neuroepithelial tumor 
with H3 G34 mutation (NET-H3-G34), and 4) poly-
morphous low-grade neuroepithelial tumor of the 
young (PLNTY)3-9. Additionally, a fifth HGNET or 
HGNET, not elsewhere classified (HGNET-NEC) is 
now being used in some clinical reports for malig-
nant CNS neoplasms that don’t fit neatly into a 
well-delineated tumor type, although some of 
these descriptive diagnoses are eventually replaced 
by a more specific one with further molecular test-
ing. 
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The Oxford dictionary definition of neuroepi-
thelium is: “1. A type of epithelium containing sen-
sory nerve endings and found in certain sense or-
gans (e.g. the retina, the inner ear, the nasal mem-
branes, and the taste buds)” or more pertinent to 
NET, “2. (in embryology) ectoderm that develops 
into nerve tissue.” 
(https://www.lexico.com/en/definition/neuroepitheli
um). Other definitions similarly focus on brain de-
velopment. For instance, according to Wikipedia, 
“neuroepithelial cells, or neuroectodermal cells, 
form the wall of the closed neural tube in early 
embryonic development. The neuroepithelial cells 
span the thickness of the tube's wall, connecting 
with the pial surface and with the ventricular or 
lumenal surface. They are joined at the lumen of 
the tube by junctional complexes, where they form 
a pseudostratified layer of epithelium called neu-
roepithelium. Neuroepithelial cells are the stem 
cells of the central nervous system, known as neu-
ral stem cells, and generate the intermediate pro-
genitor cells known as radial glial cells, that differ-
entiate into neurons and glia in the process of neu-
rogenesis.” 
(https://en.wikipedia.org/wiki/Neuroepithelial_cell). 
This explains the intended use of neuroepithelial 
tumor in the original 1988 description of DNET10, 
wherein the authors emphasized their view that 
DNET is likely related to a developmental disorder 
or malformation, given the frequent histologic find-
ings resembling focal cortical dysplasia in adjacent 
cortex. 
In other circumstances, NET is utilized in a 
broader fashion to state a belief that a neoplasm is 
derived from CNS precursor cells. Unfortunately, 
NET is now often utilized in an even less specific 
manner, essentially meaning: “I think this is proba-
bly a CNS tumor because it’s located there, but I 
wouldn’t swear to it under oath in a court of law”. 
As long as the entire oncology team knows that this 
diagnosis represents our mea culpa of ignorance, 
then there’s no harm in using this term as a place-
holder until we know more. However, busy people 
(including oncologists) often generalize and may 
assume that given the similar terminology, HGNET, 
NEC is equivalent to HGNET-MN1 (replacing mostly 
what was previously diagnosed as astroblastoma, 
mainly behaving as WHO grade II) or to HGNET-
BCOR and NET-H3-G34 (both behaving predomi-
nantly as WHO grade IV tumors). In other words, 
one could falsely assume that all HGNETs are bio-
logically related and should therefore be treated in 
a similar fashion clinically. 
Another major source of confusion comes 
from very different uses of “NET” by various ex-
perts. As already mentioned, in the past, it was an 
abbreviation for neuroectodermal tumor within 
both central and peripheral forms of PNET. In neu-
ropathology, it is now being used for neuroepithe-
lial tumor as already discussed, but outside the 
CNS, NET is currently utilized far more commonly as 
an abbreviation for neuroendocrine tumor11. This 
newly sanctioned WHO term represents the lower 
grade or well differentiated subtype of “neuroen-
docrine neoplasm”. In other words, this is the more 
favorable tumor type, but nevertheless one that 
occasionally behaves more aggressively; in turn, 
NET needs to be distinguished from neuroendo-
crine carcinoma, which is the overtly malignant and 
high-grade form of disease. Within neuropathology, 
the most common manifestation of this newly pro-
posed nomenclature is the pituitary neuroendo-
crine tumor or PitNET, in place of pituitary adeno-
ma12,13. Nonetheless, with so many different ver-
sions now entering the medical lexicon, no-one 
should be surprised if one NET subtype is confused 
for another. 
In conclusion, by discarding PNET (i.e., WHO 
grade IV small blue cell tumor with neuronal fea-
tures) in favor of NET or HGNET, have we essential-
ly exchanged our trash can for an industrial size 
dumpster? I occasionally wake up in a sweat from 
dreaming of a dystopic future wherein the WHO 
scheme is simply composed of a long list of entities 
all entitled “neuroepithelial tumor with ___ molec-
ular alteration”. Wouldn’t it be preferable to go as 
far as we can with what we know? In other words, 
if a tumor shows compelling astrocytic features, 
why not invoke astrocytoma or astrocytic neoplasm 
in the name? If the tumor has glioneuronal fea-
tures, why not say so? If indeed, neuroepithelial 
tumor is the best we can do, then at least, let’s 
make a concerted effort to replace the name once 
we know more. Of course, this is just one man’s 
opinion and an opinion is only worth the price one 
pays for it! 
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